Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.42 |
| ▸ | GRM5 | P41594 | 4/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998823 | 0.84 | CCR1 (0.46) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL7000468 | 0.81 | CCR1 (0.47) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6996406 | 0.81 | CCR1 (0.42) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL7000678 | 0.79 | CCR1 (0.50) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6997012 | 0.78 | KDM4E (0.52) | CCR1GLAHTTSMN1; SMN2MEN1 | |
| SCHEMBL7001038 | 0.78 | MEN1 (0.45) | CCR1FPR3GPR65GPR35POLB | |
| SCHEMBL6996044 | 0.77 | CCR1 (0.41) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6076312 | 0.77 | CCR1 (0.73) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6996562 | 0.76 | POLB (0.54) | CCR1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6993764 | 0.76 | CCR1 (0.61) | CCR1FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | CCR1 7/4885PTGDR2 734/4885GRM5 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.